ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
B-Cell Chronic Lymphocytic Leukemia
Follicular Lymphoma

Lymphoma trials near Madrid, MD, ESP:

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Obinutuzumab
Drug: CC-99282

Phase 1, Phase 2

Celgene
Celgene

Madrid, Spain and 68 other locations

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.ARV-3...

Enrolling
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393

Phase 1

Arvinas
Arvinas

Madrid, Spain and 16 other locations

Locations recently updated

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Madrid, Spain and 71 other locations

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

TrAVeRse is a multicentre, open-label, Phase II study of AVR in treatment naïve MCL participants. The primary objective will be to assess the rate of...

Active, not recruiting
Mantle Cell Lymphoma (MCL)
Drug: Venetoclax
Drug: Rituximab

Phase 2

AstraZeneca
AstraZeneca

Madrid, Spain and 28 other locations

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma...

Enrolling
B-cell Non-Hodgkin Lymphoma
B-cell Lymphoma
Drug: IKS03

Phase 1

Iksuda Therapeutics

Madrid, Spain and 12 other locations

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back af...

Enrolling
Marginal Zone Lymphoma (MZL)
Relapsed/Refractory Follicular Lymphoma
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Madrid, Spain and 162 other locations

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...

Active, not recruiting
Relapsed/Refractory Peripheral T-Cell Lymphoma
Adult T Cell Leukemia/Lymphoma
Drug: Valemetostat Tosylate

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Madrid, Spain and 59 other locations

Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma (LATE-R-GEL-23)

Single-arm, open-label, multicenter, phase II trial aiming to include approximately 45 patients over 24 months. Patients will receive axicabtagene ci...

Enrolling
DIFFUSE LARGE B-CELL LYMPHOMA
Drug: Axicabtagene Ciloleucel

Phase 2

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Madrid, Madrid, Spain and 14 other locations

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)

and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Hodgkin Disease
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Madrid, Spain and 76 other locations

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Loncastuximab Tesirine
Drug: Polatuzumab Vedotin

Phase 1

ADC Therapeutics

Madrid, Spain and 41 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems